P110drug The dominant search intent for "p110 peptide" is to understand what this specific peptide is, its mechanism of action, and its potential therapeutic applications, particularly in the context of neurodegenerative diseases and mitochondrial health.
Tier 1 entities and phrases:
* p110 peptide
* dynamin-related protein 1 (Drp1) inhibitor
* mitochondrial fission
* neuroprotection/neuroprotective
* therapeutic potential
Tier 2 entities and phrases:
* seven-amino acid peptide
* mitochondrial dynamics
* Drp1 GTPase activity
* Alzheimer's disease
* Huntington's disease
* amyotrophic lateral sclerosis (ALS)
* reactive oxygen species (ROS)
* mitochondrial health
* cell permeability (TAT47-57)
* inhibit Drp1/Fis1 interaction
Tier 3 entities and phrases:
* p110 protein (distinct from peptide)
* p110 drug (implies a more developed therapeutic, P110 peptide is primarily research-based)
* PI3K p110 alpha/beta (these are different proteins entirely and a common point of confusion)
---
The p110 peptide is a specialized seven-amino acid molecule that has garnered significant attention for its role as a dynamin-related protein 1 (Drp1) inhibitor. Its primary mechanism of action involves preventing mitochondrial fission, a cellular process crucial for regulating mitochondrial health and overall cellular function.Allison Reiss - Therapeutic Potential of P110 Peptide By targeting Drp1, the p110 peptide offers a distinct avenue for therapeutic intervention, particularly in conditions characterized by dysregulated mitochondrial dynamics and oxidative stress, holding considerable therapeutic potential for various diseases.
Mitochondria, the powerhouses of the cell, are dynamic organelles that constantly undergo fusion and fission. While balanced fission and fusion are essential for maintaining healthy mitochondria, excessive or aberrant fission can lead to mitochondrial dysfunction, cellular damage, and the development of various pathologies. Dynamin-related protein 1 (Drp1) is a key protein that orchestrates mitochondrial fission. It is recruited to the mitochondrial outer membrane, where its GTPase activity drives the constriction and scission of mitochondria.DRP1 Inhibitors
The p110 peptide specifically targets and inhibits the GTPase activity of Drp1, thereby preventing excessive mitochondrial fission. This targeted inhibition is critical because it aims to restore a more balanced state of mitochondrial dynamics without broadly disrupting other essential cellular processes. Unlike some other compounds, p110 peptide has shown selectivity, primarily affecting Drp1 and not other dynamin-related proteins.
The ability of the p110 peptide to prevent excessive mitochondrial fission has significant implications for neuroprotection and the treatment of neurodegenerative diseases. Conditions such as Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) are often associated with mitochondrial dysfunction, increased oxidative stress, and neuronal cell death.
Research indicates that p110 peptide can mitigate pathologies linked to these diseases.View 3 PI 3-Kinasep110beta Small Molecules andPeptides. Bio-Techne offers high-quality reagents, instruments, custom manufacturing and testing services. By inhibiting Drp1, it helps to:
* Restore Mitochondrial Dynamics: Prevents the fragmentation of mitochondria, preserving their structure and function.
* Reduce Oxidative Stress: Excessive fission can lead to the production of reactive oxygen species (ROS).P110Sale. 目录号: GC50599. Dynamin-related protein 1 (Drp1) inhibitor ... GC36670 Myelin Oligodendrocyte GlycoproteinPeptide(35-55), mouse, rat (TFA) ... Inhibiting fission can thus lower ROS levels, protecting cells from oxidative damageBuy PIK3CA blockingpeptide, PI3Kp110alpha BlockingPeptide-NP_006209.2 (MBS8232316) product datasheet at MyBioSource, BlockingPeptides..
* Improve Neuronal Health: Studies suggest that p110 peptide can rescue neurons from various insults, including anesthetic-induced cell death and damage caused by neurotoxins like MPTP. Its ability to inhibit Drp1's translocation to mitochondria, a key step in toxin-induced damage, further supports its neuroprotective role.
* Modulate Protein Aggregation: Some research points to an inhibitory effect of p110 on the formation of amyloid-beta (Aβ) plaques, a hallmark of Alzheimer's disease, thereby indirectly enhancing neuronal health.
A challenge with peptide-based therapeutics is their often limited cell permeability, which can hinder their effectiveness within cells. To address this, the p110 peptide has been conjugated with cell-penetrating sequences, such as TAT47-57.TAT-P110/P110 peptide This modification enhances its ability to cross cell membranes, allowing it to reach its mitochondrial targets more effectively and exert its therapeutic effects in preclinical models of neurodegenerative diseases.
It is important to distinguish the p110 peptide from other entities with similar naming conventions. The p110 peptide discussed here is a research tool and potential therapeutic agent targeting Drp1. This is distinct from:
* P110 protein: A general term that could refer to various proteins named "p110," including subunits of PI 3-kinasesP110 | Dynamin Inhibitors: Tocris Bioscience.
* PI 3-Kinase p110 alpha or beta: These are catalytic subunits of phosphoinositide 3-kinases, a different class of enzymes involved in cell growth, proliferation, and survival signaling pathways.作者：S Hao·2025—P110has been shown to reduce pathologies associated with various diseases, including Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, ... While also referred to as "p110," their function and therapeutic targets are unrelated to the Drp1-inhibiting peptide.
* P110 drug: This term might imply a fully developed pharmaceutical product, whereas the p110 peptide is primarily in the research and development phaseNew therapeutics to modulate mitochondrial dynamics and ....
The p110 peptide represents a promising therapeutic strategy targeting a fundamental cellular process—mitochondrial fission. Its demonstrated efficacy in preclinical models for neurodegenerative diseases, coupled with its neuroprotective and anti-oxidative properties, underscores its potential. Ongoing research is focused on further elucidating its mechanisms of action, optimizing its delivery, and evaluating its safety and efficacy in more advanced studies. As our understanding of mitochondrial dynamics in disease progression deepens, targeted inhibitors like the p110 peptide are poised to play an increasingly vital role in the development of novel treatments for a range of debilitating conditions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.